David Amsellem

Piper Sandler | Healthcare

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #2161 out of 4773 analysts, they have issued 48 stock ratings with a success rate of 72.55% and an average return of 17.85%.

David Amsellem has a well-established track record, with 48 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 72.55% and an average return of 17.85%, underscoring their expertise and ability to identify winning opportunities for investors.

#2161

Out of 4773

48

Total Ratings

+72.55%

Success Rate

+17.85%

Average Return

Recent Ratings Analysis

BIIB

Sep 03, 2026

Target

$245.00

Current

$217.15

Performance

-3.28%

David Amsellem rated BIIB as Overweight on Sep 03, 2026, setting a price target of 245. Shares have remained stable near 217.15, leaving the 245 target still in play.

AMGN

Aug 20, 2026

Target

$457.00

Current

$377.35

Performance

-13.00%

On Aug 20, 2026, AMGN was given a Overweight rating by David Amsellem, with a target price of 457. Despite the Buy call, shares fell from 377.35 to 377.35, challenging the optimistic stance.

ABBV

Aug 20, 2026

Target

$303.00

Current

$257.06

Performance

-1.82%

ABBV received a Overweight rating from David Amsellem on Aug 20, 2026, aiming for 303. Price action was muted, as shares hovered around 257.06 despite the bullish outlook.

JAZZ

Aug 04, 2026

Target

$310.00

Current

$245.80

Performance

-6.05%

On Aug 04, 2026, David Amsellem published a Overweight outlook on JAZZ, with a target of 310. Market action contradicted the Buy thesis, as shares slipped to 245.8.

NBIX

Jul 31, 2026

Target

$210.00

Current

$156.22

Performance

-6.34%

David Amsellem on Jul 31, 2026 assigned NBIX a Overweight rating, with a price target of 210. The call has struggled to gain traction, with shares losing 6.34%.

CORT

Jul 30, 2026

Target

$165.00

Current

$112.79

Performance

-4.67%

On Jul 30, 2026, David Amsellem reaffirmed CORT with a Overweight rating, targeting 165. Market indecision has kept the 165 target in a holding pattern.

TEVA

Jul 28, 2026

Target

$44.00

Current

$37.09

Performance

17.11%

TEVA was rated Overweight by David Amsellem on Jul 28, 2026, with a price objective of 44. A bullish response from the market helped close the gap of 6.91 to the target.

ALKS

Jul 28, 2026

Target

$65.00

Current

$45.97

Performance

-8.97%

On Jul 28, 2026, David Amsellem initiated coverage on ALKS with a Overweight rating and target of 65. The Buy call has yet to be validated as shares remain 19.03 away from the target.

DFTX

Jul 24, 2026

Target

$73.00

Current

$38.89

Performance

-9.91%

David Amsellem issued a Overweight recommendation for DFTX on Jul 24, 2026, price target set at 73. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

AMPH

May 11, 2026

Target

$21.00

Current

$23.78

Performance

28.89%

On May 11, 2026, AMPH was evaluated by David Amsellem, who gave a Neutral rating and target of 21. Investors who stayed in despite the Hold saw upside of 28.89%.

OGN

Apr 28, 2026

Target

$14.00

Current

$13.64

Performance

2.40%

David Amsellem rated OGN as Neutral on Apr 28, 2026, setting a price target of 14. The Hold stance appears justified, as shares hovered around 13.64 with a 2.40% move.

PTHS

Feb 27, 2026

Target

$48.00

Current

$21.90

Performance

-16.92%

On Feb 27, 2026, PTHS was given a Overweight rating by David Amsellem, with a target price of 48. Despite the Buy call, shares fell from 21.9 to 21.9, challenging the optimistic stance.

BMY

Feb 23, 2026

Target

$75.00

Current

$63.64

Performance

3.90%

BMY received a Overweight rating from David Amsellem on Feb 23, 2026, aiming for 75. Price action was muted, as shares hovered around 63.64 despite the bullish outlook.

VTRS

Jan 28, 2026

Target

$12.00

Current

$16.51

Performance

27.29%

On Jan 28, 2026, David Amsellem published a Neutral outlook on VTRS, with a target of 12. The Hold call missed some of the bullish momentum as shares advanced toward 12.

AXSM

Jan 16, 2026

Target

$223.00

Current

$220.75

Performance

24.53%

David Amsellem on Jan 16, 2026 assigned AXSM a Overweight rating, with a price target of 223. The Buy call aligned well with market performance, producing a gain of 24.53%.

FENC

Jan 09, 2026

Target

$18.00

Current

$10.96

Performance

41.06%

On Jan 09, 2026, David Amsellem reaffirmed FENC with a Overweight rating, targeting 18. The recommendation was supported by strong follow-through as the stock rose from 10.96 to 10.96.

ESPR

Nov 25, 2025

Target

$9.00

Current

$3.18

Performance

-13.82%

ESPR was rated Overweight by David Amsellem on Nov 25, 2025, with a price objective of 9. This case shows how bullish projections can fail, with the stock now below 3.18.

XERS

Nov 07, 2025

Target

$8.00

Current

$7.45

Performance

0.27%

On Nov 07, 2025, David Amsellem initiated coverage on XERS with a Neutral rating and target of 8. The stock’s lack of movement around 7.45 aligned with a cautious approach.

AQST

Nov 07, 2025

Target

$8.00

Current

$4.78

Performance

-20.86%

David Amsellem issued a Overweight recommendation for AQST on Nov 07, 2025, price target set at 8. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

INDV

Oct 31, 2025

Target

$41.00

Current

$34.49

Performance

17.43%

On Oct 31, 2025, INDV was evaluated by David Amsellem, who gave a Overweight rating and target of 41. This case illustrates how a timely bullish rating can translate into tangible gains of 17.43%.

AMRX

Oct 31, 2025

Target

$13.00

Current

$17.01

Performance

57.21%

David Amsellem rated AMRX as Overweight on Oct 31, 2025, setting a price target of 13. The call has proven timely, with shares rising 57.21% toward the price target of 13.

SUPN

Oct 09, 2025

Target

$65.00

Current

$41.64

Performance

-15.90%

On Oct 09, 2025, SUPN was given a Overweight rating by David Amsellem, with a target price of 65. Despite the Buy call, shares fell from 41.64 to 41.64, challenging the optimistic stance.

SAGE

Jun 17, 2025

Target

$8.50

Current

$8.68

Performance

-4.82%

SAGE received a Neutral rating from David Amsellem on Jun 17, 2025, aiming for 8.5. Shares remained flat at 8.68, aligning with the neutral rating.

OPTN

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

On Mar 21, 2025, David Amsellem published a Neutral outlook on OPTN, with a target of 9. Sideways action left the Hold view intact, with no major move since 9.6.

COLL

Feb 04, 2025

Target

$36.00

Current

$22.75

Performance

-26.45%

David Amsellem on Feb 04, 2025 assigned COLL a Neutral rating, with a price target of 36. The call successfully avoided chasing as shares lost 26.45%.

ITCI

Jan 14, 2025

Target

$132.00

Current

$131.87

Performance

3.92%

On Jan 14, 2025, David Amsellem reaffirmed ITCI with a Neutral rating, targeting 132. The neutral call matched muted market action of 3.92%.

AVDL

Jan 10, 2025

Target

$13.00

Current

$21.64

Performance

173.92%

AVDL was rated Overweight by David Amsellem on Jan 10, 2025, with a price objective of 13. A bullish response from the market helped close the gap of -8.64 to the target.

ANIP

Oct 11, 2024

Target

$68.00

Current

$70.19

Performance

22.84%

On Oct 11, 2024, David Amsellem initiated coverage on ANIP with a Overweight rating and target of 68. The stock’s climb of 22.84% since the call highlights the foresight in the rating.

BHC

Aug 02, 2024

Target

$3.00

Current

$5.86

Performance

4.09%

David Amsellem issued a Underweight recommendation for BHC on Aug 02, 2024, price target set at 3. Investors remain in wait-and-see mode as shares stayed flat.

PCRX

Jul 03, 2024

Target

$42.00

Current

$25.36

Performance

17.08%

On Jul 03, 2024, PCRX was evaluated by David Amsellem, who gave a Overweight rating and target of 42. This case illustrates how a timely bullish rating can translate into tangible gains of 17.08%.

RVNC

May 10, 2024

Target

$11.00

Current

$3.65

Performance

9.94%

David Amsellem rated RVNC as Overweight on May 10, 2024, setting a price target of 11. The call has proven timely, with shares rising 9.94% toward the price target of 11.

Frequency Asked Questions

Who is David Amsellem?

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector.

What is David Amsellem's success rate?

David Amsellem currently has a success rate of +72.55%.

How many ratings has David Amsellem issued?

David Amsellem has issued 48 stock ratings so far.

What is the average return of David Amsellem's calls?

Their stock ratings have generated an average return of +17.85%.

What is David Amsellem's ranking?

David Amsellem is ranked #2161 out of 4773 analysts.

What types of ratings does David Amsellem give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Amsellem?

You can follow David Amsellem by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Amsellem?

Their latest rating was a Buy on BIIB issued on 2026-09-03.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep